Home › NDC Lookup › Ingredients › Prednisone › 63561-0120-02
PredniSONE Tablets, USP, 5 mg 5 mg Tablet, 1,000-count — NDC 63561-0120-02 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

PredniSONE Tablets, USP, 5 mg 5 mg Tablet, 1,000-count — NDC 63561-0120-2 (Billing 63561-0120-02)

by Granulation Technology, Inc. · 1000 TABLET in 1 BOTTLE

This is a package of 1,000 tablets of PredniSONE Tablets, USP, 5 mg 5 mg Tablet from Granulation Technology, Inc., marketed since May 2025 and currently FDA-listed; retail pharmacies pay about $0.0367 per tablet (NADAC).

NDC 63561-0120-02
🏷️ FDA NDC (as labeled) 63561-0120-2 billing pads the package segment with a zero
This package
Contains1,000-count Cost per ea$0.0367 NADAC Per package$36.70 / 1000 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.4821/unit — full pricing hub ↓
Product page 63561-0120-01 Also comes in: 100 tablets 63561-0120-1 500 tablets 63561-0120-5
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 63561-0120-2
Product NDC 63561-0120
11-digit billing NDC 63561012002
NCPDP billing unit EA — each (per item)
RxCUI 198145, 312615, 312617
UNII VB0R961HZT
UPC 0363561012012, 0363561012210, 0363561012159
Application # ANDA212629
SPL Set ID a173fcbb-99be-4b3e-a3a4-4e9ae04ad83f
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2025-05-22
Route ORAL
Dosage form TABLET
Substance PREDNISONE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 22100045000315
GCN Seq No 006753
GCN 27176
HICL code 002879
Ingredient (HICL) Prednisone
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P5
Therapeutic class — intermediate (HIC2) Adrenocortical Hormones
HIC3 code P5A
Therapeutic class — specific (HIC3) Glucocorticoids
AHFS code 68:04.00.00
AHFS class Adrenals
FDB label name PREDNISONE 5 MG TABLET
FDB brand name Prednisone
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 006753
  • GCN: 27176
  • GPI-14 (Medi-Span): 22100045000315
  • HICL (First Databank): 002879
  • AHFS class code: 68:04.00.00
  • RxCUI (RxNorm): 198145
Why two NDCs? The FDA registers this code as 63561-0120-2 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 63561-0120-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids acting locally, Glucocorticoids
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PREDNISONE 5 MG TABLET Ingredient Prednisone
📗 Our plain-language guide HelloPharmacist
  • It calms inflammation and lowers immune activity. It is used for allergies, arthritis, lupus, skin, gut, lung, eye and blood conditions, and more. Your prescriber chose it for your...
  • Take it with food or milk to protect your stomach. A once-daily dose is usually best in the morning. If you have delayed-release tablets, take them with food and swallow them whole...
  • No, not after long-term use. Your body may need time to restart its own steroid production. Your doctor will lower the dose gradually.
  • Bigger appetite, weight gain, trouble sleeping, mood swings and stomach upset are common. Call your doctor for signs of infection, black stools, severe stomach pain, vision changes...
📖 Read our full Prednisone guide →
8
Nutrient depletion considerations

Prednisone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Prednisone nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.037 $36.70 / 1000 tablets
Medicaid paysCMS SDUD · 12 mo $0.4821 $482.10 / 1000 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Jun 2026 Jul 2026 Aug 2026 Sep 2026 $0.037 $0.036
Flat over the last 4 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
63561-0120-01 63561-0120-1 Main listing 100 TABLET in 1 BOTTLE $0.0367 / ea $3.67 2025-05-22 — Active
63561-0120-02 You're viewing this 1000 TABLET in 1 BOTTLE $0.0367 / ea $36.69 2025-05-22 — Active
63561-0120-05 63561-0120-5 500 TABLET in 1 BOTTLE $0.0367 / ea $18.35 2025-05-22 — Active

You're viewing the largest of 3 pack sizes for this product.

This pack effectively ties for the lowest per-ea cost of the 3 priced pack sizes ($0.0367 NADAC).

Pack size FAQ

What quantity is in this package?
This is a 1,000-count package — 1000 tablet in 1 bottle.
How does this package differ from NDC 63561-0120-01?
Both are PredniSONE Tablets, USP, 5 mg 5 mg Tablet — the drug itself is identical. This page's package is the 1,000-count one, while NDC 63561-0120-01 is the 100 tablets package.
What NDC number is used to bill for this package of PredniSONE Tablets, USP, 5 mg 5 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
PredniSONE 5 mg 00054-9828-25 Hikma 100 tablets $0.037 AB Availability likely —
Prednisone 5 mg 00378-0640-01 Mylan 100 tablets $0.037 — Availability likely —
Prednisone 5 mg 00591-5052-01 Actavis 100 tablets $0.037 — Availability likely —
Prednisone 5 mg 59651-0486-01 Aurobindo 100 tablets $0.037 AB Availability likely —
prednisone 5 mg 60219-1706-01 Amneal 100 tablets $0.037 AB Availability likely —
Prednisone 5 mg 60687-0122-01 American 100 tablets $0.037 AB Availability likely —
prednisone 5 mg 60687-0903-01 American 100 tablets $0.037 AB Availability likely —
Prednisone 5 mg 62135-0471-18 Chartwell 180 tablets $0.037 — Availability likely —
PredniSONE Tablets, USP, 5 mgthis 63561-0120-02 Granulation 1000 tablets $0.037 AB Availability likely —
Prednisone 5 mg 70954-0058-10 ANI 100 tablets $0.037 AB Availability likely —
PredniSONE 5 mg 00054-4728-25 Hikma 100 tablets $0.045 AB FDA listed +22%
PredniSONE 5 mg 00054-8724-25 Hikma 100 tablets $0.045 AB FDA listed +22%
Prednisone 5 mg 00603-5337-15 Par 21 tablets $0.337 AB Availability likely +818%
prednisone 5 mg 00615-8439-05 NCS 15 tablets — AB FDA listed —
Prednisone 5 mg 10135-0776-01 Marlex 100 tablets — AB FDA listed —
Prednisone 5 mg 42708-0114-21 QPharma, 21 tablets — AB FDA listed —
Prednisone 5 mg 42708-0136-21 QPharma, 21 tablets — — FDA listed —
PredniSONE 5 mg 43063-0968-21 PD-Rx 21 tablets — AB FDA listed —
Prednisone 5 mg 50090-3354-00 A-S 21 tablets — AB FDA listed —
Prednisone 5 mg 50090-3361-04 A-S 40 tablets — AB FDA listed —
prednisone 5 mg 50090-5814-00 A-S 21 tablets — — FDA listed —
PredniSONE 5 mg 50090-6619-00 A-S 21 tablets — AB FDA listed —
PredniSONE 5 mg 50090-6621-06 A-S 90 tablets — AB FDA listed —
PredniSONE 5 mg 50090-6623-00 A-S 90 tablets — AB FDA listed —
Prednisone 5 mg 50090-7124-00 A-S 90 tablets — AB FDA listed —
prednisone 5 mg 50090-7505-00 A-S 90 tablets — AB FDA listed —
prednisone 5 mg 50090-7684-00 A-S 21 tablets — AB FDA listed —
prednisone 5 mg 50090-7686-06 A-S 90 tablets — AB FDA listed —
prednisone 5 mg 50090-7688-00 A-S 90 tablets — AB FDA listed —
Prednisone 5 mg 50090-7931-00 A-S 21 tablets — AB FDA listed —
Prednisone 5 mg 50090-7933-00 A-S 42 tablets — AB FDA listed —
Prednisone 5 mg 50090-7935-00 A-S 90 tablets — AB FDA listed —
Prednisone 5 mg 51407-0921-10 Golden 1000 tablets — — FDA listed —
prednisone 5 mg 51655-0068-21 Northwind 21 tablets — — FDA listed —
PredniSONE 5 mg 51655-0355-26 Northwind 90 tablets — AB FDA listed —
Prednisone 5 mg 51655-0765-21 Northwind 21 tablets — — FDA listed —
prednisone 5 mg 51655-0988-21 Northwind 21 tablets — AB FDA listed —
Prednisone 5 mg 55154-2146-00 Cardinal 10 tablets — AB FDA listed —
prednisone 5 mg 55154-2582-00 Cardinal 10 tablets — AB FDA listed —
PredniSONE 5 mg 60760-0796-21 St. 21 tablets — AB FDA listed —
Prednisone 5 mg 63187-0020-10 Proficient 10 tablets — AB FDA listed —
Prednisone 5 mg 63187-0066-05 Proficient 5 tablets — AB FDA listed —
Prednisone 5 mg 63187-0997-05 Proficient 5 tablets — AB FDA listed —
Prednisone 5 mg 63629-1605-00 Bryant 42 tablets — AB FDA listed —
Prednisone 5 mg 63629-2264-01 Bryant 100 tablets — AB FDA listed —
prednisone 5 mg 64380-0783-01 Strides 100 tablets — AB FDA listed —
prednisone 5 mg 67046-1642-03 Coupler 30 tablets — AB FDA listed —
Prednisone 5 mg 67544-0399-60 Aphena 90 tablets — AB FDA listed —
PredniSONE 5 mg 68071-3581-01 NuCare 100 tablets — AB FDA listed —
Prednisone 5 mg 68071-3729-01 NuCare 21 tablets — AB FDA listed —
Prednisone 5 mg 68071-3742-01 NuCare 100 tablets — AB FDA listed —
prednisone 5 mg 68788-8579-03 Preferred 30 tablets — — FDA listed —
Prednisone 5 mg 68788-9551-02 Preferred 21 tablets — AB FDA listed —
Prednisone 5 mg 70518-3537-00 REMEDYREPACK 21 tablets — AB FDA listed —
prednisone 5 mg 70518-3539-00 REMEDYREPACK 30 tablets — AB Discontinued —
PredniSONE 5 mg 70518-4271-00 REMEDYREPACK 100 tablets — AB FDA listed —
Prednisone 5 mg 70882-0117-21 Cambridge 21 tablets — AB Discontinued —
Prednisone 5 mg 71335-0508-00 Bryant 42 tablets — AB Discontinued —
Prednisone 5 mg 71335-1780-00 Bryant 42 tablets — AB FDA listed —
prednisone 5 mg 71335-2134-00 Bryant 42 tablets — AB FDA listed —
PredniSONE Tablets, USP, 5 mg 71335-2753-00 Bryant 42 tablets — AB FDA listed —
PredniSONE Tablets, USP, 5 mg 71335-3042-01 Bryant 100 tablets — AB FDA listed —
PredniSONE Tablets, USP, 5 mg 71335-3043-01 Bryant 1000 tablets — AB FDA listed —
Prednisone 5 mg 71610-0834-30 Aphena 30 tablets — AB FDA listed —
Prednisone 5 mg 72162-2149-00 Bryant 1000 tablets — — FDA listed —
PredniSONE Tablets, USP, 5 mg 72162-2484-00 Bryant 1000 tablets — AB FDA listed —
Prednisone 5 mg 72189-0593-21 Direct_Rx 21 tablets — — FDA listed —
Prednisone 5 mg 72789-0413-21 PD-Rx 21 tablets — AB FDA listed —
PredniSONE Tablets, USP, 5 mg 72789-0474-01 PD-Rx 100 tablets — AB FDA listed —
PredniSONE Tablets, USP, 5 mg 72789-0498-30 PD-Rx 30 tablets — AB FDA listed —
Prednisone 5 mg 76420-0067-21 Asclemed 21 tablets — AB FDA listed —
Prednisone 5 mg 80425-0068-01 Advanced 21 tablets — AB FDA listed —
Prednisone 5 mg 80425-0069-01 Advanced 21 tablets — AB FDA listed —
Prednisone 5 mg 80425-0106-01 Advanced 21 tablets — AB FDA listed —
Prednisone 5 mg 80425-0479-01 Advanced 21 tablets — AB FDA listed —
PredniSONE 5 mg 80425-0480-01 Advanced 21 tablets — AB FDA listed —
PredniSONE 5 mg 80425-0481-01 Advanced 21 tablets — AB FDA listed —
prednisone 5 mg 80425-0482-01 Advanced 21 tablets — AB FDA listed —
Prednisone 5 mg 82804-0223-10 Proficient 10 tablets — AB FDA listed —
Prednisone 5 mg 87063-0043-01 ASCLEMED 100 tablets — AB FDA listed —
prednisone 5 mg 42708-0186-21 QPharma 21 tablets — AB FDA listed —
Prednisone 5 mg 61919-0365-21 DIRECT 21 tablets — AB FDA listed —
Prednisone 5 mg 70518-0305-00 REMEDYREPACK 21 tablets — AB FDA listed —
Prednisone 5 mg 66267-0172-06 NuCare 6 tablets — AB FDA listed —
Prednisone 5 mg 63629-2261-01 Bryant 21 tablets — AB Discontinued —
Prednisone 5 mg 50090-0439-00 A-S 21 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
On the market since
May 2025
📍
2026
Currently FDA-listed
1 year listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
ImprintE173
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerGranulation Technology, Inc.
Application holderPOINTVIEW HOLDINGS LLC
FDA applicationANDA212629 (ANDA)
Labeler code63561
First marketedMay 2025
Product typeHuman Prescription Drug
Portfolio16 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage ~2 min read ▾

INDICATIONS AND USAGE Prednisone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3.

Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6.

Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.

Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13.

Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION The initial dosage of prednisone may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted.

If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT . After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient’s condition.

If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Multiple Sclerosis In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.) ADT ® (Alternate Day Therapy) ADT is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning.

The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm.

Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity.

There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing’s disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted during l… [Excerpted — this section continues on DailyMed.]

⛔ Contraindications 9 words ▾

CONTRAINDICATIONS Systemic fungal infections and known hypersensitivity to components.

⚠️ Warnings ~2 min read ▾

WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including PredniSONE Tablets USP, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.

The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider PredniSONE Tablets USP withdrawal or dosage reduction as needed. Tuberculosis If PredniSONE Tablets USP is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.

Closely monitor such patients for reactivation. During prolonged PredniSONE Tablets USP therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including PredniSONE Tablets USP.

In corticosteroid-treated patients who have not had these diseases or are nonimmune, particular care should be taken to avoid exposure to varicella and measles: If a PredniSONE Tablets USP-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a PredniSONE Tablets USP-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including PredniSONE Tablets USP. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with PredniSONE Tablets USP.

For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including PredniSONE Tablets USP, may exacerbate systemic fungal infections; therefore, avoid PredniSONE Tablets USP use in the presence of such infections unless PredniSONE Tablets USP is needed to control drug reactions. For patients on chronic PredniSONE Tablets USP therapy who develop systemic fungal infections, PredniSONE Tablets USP withdrawal or dosage reduction is recommended.

Amebiasis Corticosteroids, including PredniSONE Tablets USP, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating PredniSONE Tablets USP in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including PredniSONE Tablets USP, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.

In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gramnegative septicemia. Cerebral Malaria Avoid corticosteroids, including PredniSONE Tablets USP, in patients with cerebral malaria. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions 173 words ▾

ADVERSE REACTIONS Fluid and Electrolyte Disturbances Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests Metabolic Negative nitrogen balance due to protein catabolism Neurological Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Menstrual irregularities Development of Cushingoid state Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Suppression of growth in children Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Additional Reactions Urticaria and other allergic, anaphylactic or hypersensitivity reactions

📦 How Supplied / Storage and Handling 174 words ▾

HOW SUPPLIED PredniSONE Tablets USP, 5 mg, 10 mg and 20 mg 5 mg – White, round, scored tablets, debossed "Є 171" on one side, plain and scored on the other side. NDC 63561-0120-01: Bottle of 100 Tablets NDC 63561-0120-05: Bottle of 500 Tablets NDC 63561-0120-02: Bottle of 1,000 Tablets 10 mg – White, round, scored tablets, debossed "Є 172" on one side, plain and scored on the other side. NDC 63561-0121-01: Bottle of 100 Tablets NDC 63561-0121-05: Bottle of 500 Tablets NDC 63561-0121-02: Bottle of 1,000 Tablets 20 mg – White, round, scored tablets, debossed "Є 173" on one side, plain and scored on the other side.

NDC 63561-0122-01: Bottle of 100 Tablets NDC 63561-0122-05: Bottle of 500 Tablets NDC 63561-0122-02: Bottle of 1,000 Tablets Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight, child-resistant container as defined in the USP/NF. PROTECT FROM MOISTURE.

Manufactured by: Granulation Technology, Inc. Fairfield, NJ 07004, USA Revised Aug 2025

📋 Description 113 words ▾

DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.

It is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol. The chemical name for prednisone is 17,21-dihydroxypregna-1,4-dienne-3,11,20-trione. The structural formula is represented below: C 21 H 26 O 5 M.W.

358.44 Each tablet, for oral administration, contains 5, 10, or 20 mg of prednisone. Inactive Ingredients: PredniSONE Tablets, USP contain the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, colloidal silicon dioxide and talc. Meets USP Dissolution Test 2. chem-pred.jpg

💬 Information for Patients 29 words ▾

Information for Patients Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles and, if exposed, to obtain medical advice.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Precautions Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease.

The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see DOSAGE AND ADMINISTRATION ). Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.

Since concurrent use of these agents results in a mutual inhibition of metabolism, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Information for Patients Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles and, if exposed, to obtain medical advice.

📄 Package Label / Principal Display Panel 162 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 5 mg NDC 63561- 0120 -01 100 Tablets Rx Only btl-label-5mg-100s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 5 mg NDC 63561- 0120 -05 500 Tablets Rx Only blt-label-5mg-500s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 5 mg NDC 63561- 0120 -02 1000 Tablets Rx Only btl-label-5mg-1000s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 10 mg NDC 63561- 0121 -01 100 Tablets Rx Only btl-label-10mg-100s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 10 mg NDC 63561- 0121 -05 500 Tablets Rx Only btl-label-10mg-500s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 10 mg NDC 63561- 0121 -02 1000 Tablets Rx Only btl-label-10mg-1000s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 20 mg NDC 63561- 0122 -01 100 Tablets Rx Only btl-label-20mg-100s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 20 mg NDC 63561- 0122 -05 500 Tablets Rx Only btl-label-20mg-500s

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL PredniSONE Tablets, USP 20 mg NDC 63561- 0122 -02 1000 Tablets Rx Only btl-label-20mg-1000s

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2026 – Q1 2026 · 1 quarter of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
19
Units reimbursed last 4 qtrs
515
Gross reimbursed last 4 qtrs
$248.30
Avg / prescription
$13.07
Avg / unit
$0.4821
Latest quarter Q1 2026
19Rx
Medicaid pays / ea
$0.4821
gross reimbursed
vs
NADAC / ea
$0.0367
acquisition cost
=
Spread
+$0.4454
+1214% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% MCO
Fee-for-service · 0 Rx Managed care · 19 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 515 units · 11.3 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
11.311.3
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Louisiana 11.3 /100k
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets this page63561-0120-02 19 Rx · $248
100 tablets63561-0120-01 No Medicaid data
500 tablets63561-0120-05 No Medicaid data
Drug total (last 4 qtrs): 19 Rx · 515 units · $248 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Prednisone (matched by generic name) — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Prednisone. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.74M
Claims incl. refills
4.1M
Beneficiaries
3M
Spend / beneficiary
$5.57
Spend / claim
$4.04
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 63560-0001-04 · Memorial 63561-0121-01 · Granulation →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.